Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics

被引：14
|
作者：
Feldman, Steven R. [1 ]
Pelletier, Corey L. [2 ]
Wilson, Kathleen L. [3 ]
Mehta, Rina K. [2 ]
Brouillette, Matthew A. [3 ]
Smith, David [3 ]
Bonafede, Machaon M. [3 ]
机构：
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, Winston Salem, NC 27103 USA
[2] Celgene Corp, Summit, NJ USA
[3] IBM Watson Hlth, Cambridge, MA 02142 USA
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2019年 / 8卷 / 01期
关键词：
adherence; apremilast; healthcare costs; persistence; psoriasis;
D O I：
10.2217/cer-2018-0097
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Aim: Biologics and apremilast have advanced psoriasis management by adding treatment options. This study evaluated persistence, adherence and healthcare costs among biologic-naive patients receiving apremilast or biologics. Methods: Administrative claims data for adults starting apremilast or biologics from 1 January 2013 to 30 June 2016 were matched based on demographics. Results: Apremilast (n=703) and biologics (n=1378) had similar baseline characteristics. 12-month persistence and adherence rates were similar. Adjusted total healthcare costs were lower with apremilast versus biologics (p<0.001) due to lower total outpatient pharmacy costs (p<0.001). Conclusion: Real-world apremilast users had similar adherence and lower total healthcare costs versus biologic users. Apremilast's cost advantage was evident regardless of whether the patients were persistent or nonpersistent, or switched or did not switch treatments.
引用
收藏
页码：45 / 54
页数：10
相关论文
共 50 条
  • [1] REAL-WORLD COSTS IN BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Pelletier, C.
    Udeze, C.
    Tian, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S888 - S888
  • [2] Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    Khilfeh, Ibrahim
    Curtis, Jeffrey R.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (11) : 767 - 779
  • [3] Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 365 - 371
  • [4] REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Udeze, C.
    Pelletier, C.
    Tian, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S888 - S888
  • [5] SWITCH PATTERNS AND TOTAL COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIASIS
    Wu, J.
    Pelletier, C.
    Ung, B.
    Tian, M.
    Ni, Q.
    Curtis, J. R.
    [J]. VALUE IN HEALTH, 2018, 21 : S426 - S426
  • [6] Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis
    Feldman, Steven R.
    Pelletier, Corey L.
    Wilson, Kathleen L.
    Mehta, Rina K.
    Brouillette, Matthew A.
    Smith, David
    Bonafede, Machaon M.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (09) : 699 - 708
  • [7] Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis
    Wu, Jashin J.
    Pelletier, Corey
    Ung, Brian
    Tian, Marc
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (01) : 169 - 176
  • [8] RATES OF REAL-WORLD TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Pelletier, C.
    Udeze, C.
    Tian, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S245 - S245
  • [9] REAL WORLD COMPARISON OF PERSISTENCE AND ADHERENCE AMONG BIOLOGIC NAIVE PATIENTS INITIATING APREMILAST OR BIOLOGICS FOR THE TREATMENT OF PSORIASIS IN THE UNITED STATES
    Feldman, S. R.
    Bonafede, M. M.
    Pelletier, C.
    Mehta, R.
    Brouillette, M.
    Smith, D.
    Wilson, K. L.
    Ni, Q.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A566 - A566
  • [10] SWITCH PATTERNS AND TOTAL HEALTHCARE COSTS IN BIOLOGIC-NAIVE PATIENTS INITIATING APREMILAST OR A BIOLOGIC FOR THE TREATMENT OF PSORIATIC ARTHRITIS: RESULTS FROM A US CLAIMS ANALYSIS
    Curtis, J. R.
    Pelletier, C.
    Ung, B.
    Tian, M.
    Ni, Q.
    Wu, J.
    [J]. VALUE IN HEALTH, 2018, 21 : S293 - S294
12345